Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Capital Leases (2016 - 2018)

Editas Medicine (EDIT) has disclosed Capital Leases for 3 consecutive years, with $32.4 million as the latest value for Q4 2018.

  • On a quarterly basis, Capital Leases fell 3.03% to $32.4 million in Q4 2018 year-over-year; TTM through Dec 2018 was $32.4 million, a 3.03% decrease, with the full-year FY2018 number at $32.4 million, down 3.03% from a year prior.
  • Capital Leases was $32.4 million for Q4 2018 at Editas Medicine, down from $32.7 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $35.1 million in Q4 2016 to a low of $11.6 million in Q1 2016.
  • A 3-year average of $30.6 million and a median of $33.1 million in 2018 define the central range for Capital Leases.
  • Biggest YoY gain for Capital Leases was 191.26% in 2017; the steepest drop was 4.74% in 2017.
  • Editas Medicine's Capital Leases stood at $35.1 million in 2016, then decreased by 4.74% to $33.4 million in 2017, then dropped by 3.03% to $32.4 million in 2018.
  • Per Business Quant, the three most recent readings for EDIT's Capital Leases are $32.4 million (Q4 2018), $32.7 million (Q3 2018), and $32.9 million (Q2 2018).